The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF

Am J Kidney Dis. 2004 Jul;44(1):77-83. doi: 10.1053/j.ajkd.2004.03.024.

Abstract

Background: Patients with chronic renal failure (CRF) have a high incidence of cardiovascular disease and increased premature mortality. n-3 Polyunsaturated fatty acids (PUFAs) are known to decrease plasma triglyceride levels, reduce blood pressure (BP), and have a cardioprotective effect in subjects with normal renal function. The aim of this study is to examine the effect of n-3 PUFAs on plasma lipid and lipoprotein levels and 24-hour ambulatory BP in patients with CRF.

Methods: Sixty-four patients with CRF, defined as a plasma creatinine level between 1.70 and 4.52 mg/dL (150 and 400 micromol/L), were included and randomly assigned to treatment with 2.4 g of n-3 PUFAs or control treatment (olive oil) for 8 weeks. Patients were evaluated by measurement of fasting plasma lipid and lipoprotein levels and 24-hour ambulatory BP recordings before and after the supplements. n-3 PUFA content was determined in cell membranes of granulocytes and adipose tissue samples to evaluate n-3 PUFA intake.

Results: There was a significant 8% increase in high-density lipoprotein cholesterol levels (P < 0.01) and a significant 21% decrease in serum triglyceride levels (P < 0.02) in the group administered n-3 PUFA supplements. There were no changes in total cholesterol or low-density lipoprotein cholesterol levels in any group, and n-3 PUFAs had no effect on 24-hour ambulatory BP.

Conclusion: Supplementation with n-3 PUFAs had a favorable effect on lipoprotein profile in patients with CRF, whereas no effect on 24-hour ambulatory BP was observed.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adipose Tissue / metabolism
  • Cholesterol, HDL / blood
  • Dietary Supplements*
  • Fatty Acids, Omega-3 / administration & dosage*
  • Female
  • Fish Oils / administration & dosage*
  • Humans
  • Hypertension / complications
  • Hypertension / metabolism
  • Hypolipidemic Agents / administration & dosage
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / physiopathology*
  • Lipids / blood*
  • Lipoproteins / blood*
  • Male
  • Middle Aged
  • Triglycerides / blood

Substances

  • Cholesterol, HDL
  • Fatty Acids, Omega-3
  • Fish Oils
  • Hypolipidemic Agents
  • Lipids
  • Lipoproteins
  • Triglycerides